Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Breast Neoplasms 14Rectal Neoplasms 13Nasopharyngeal Carcinoma 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Adenocarcinoma 3Recurrence 2Pancreatic Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Non-Small-Cell Lung 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Rectal Cancer Patients 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Pancreatic Cancer Non-resectable 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Metastatic Breast Cancer in the Brain 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1

Interventions

Gemcitabine 2sintilimab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pancreatic Cancer Resectable × Capecitabine × Clear all
NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡